Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group. Cornely OA, et al. Among authors: reichert d. Clin Infect Dis. 2007 May 15;44(10):1289-97. doi: 10.1086/514341. Epub 2007 Apr 9. Clin Infect Dis. 2007. PMID: 17443465 Clinical Trial.
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Cornely OA, Wicke T, Seifert H, Bethe U, Schwonzen M, Reichert D, Ullmann AJ, Karthaus M, Breuer K, Salzberger B, Diehl V, Fätkenheuer G. Cornely OA, et al. Among authors: reichert d. Int J Hematol. 2004 Jan;79(1):74-8. doi: 10.1007/BF02983537. Int J Hematol. 2004. PMID: 14979482 Clinical Trial.
Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA, Böhme A, Reichert D, Reuter S, Maschmeyer G, Maertens J, Buchheidt D, Paluszewska M, Arenz D, Bethe U, Effelsberg J, Lövenich H, Sieniawski M, Haas A, Einsele H, Eimermacher H, Martino R, Silling G, Hahn M, Wacker S, Ullmann AJ, Karthaus M; Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology. Cornely OA, et al. Among authors: reichert d. J Antimicrob Chemother. 2008 Apr;61(4):939-46. doi: 10.1093/jac/dkn027. Epub 2008 Feb 12. J Antimicrob Chemother. 2008. PMID: 18272515
Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.
Vehreschild JJ, Böhme A, Reichert D, Kiehl MG, Arenz D, Pankraz K, Kochanek M, Ullmann AJ, Cornely OA. Vehreschild JJ, et al. Among authors: reichert d. Int J Hematol. 2008 Mar;87(2):126-131. doi: 10.1007/s12185-008-0045-z. Epub 2008 Feb 21. Int J Hematol. 2008. PMID: 18288564 Free PMC article.
Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H, Heinz W, Junghanss C, Karthaus M, Krüger W, Krug U, Kubin T, Penack O, Reichert D, Reuter S, Silling G, Südhoff T, Ullmann AJ, Maschmeyer G. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), et al. Among authors: reichert d. Ann Hematol. 2009 Feb;88(2):97-110. doi: 10.1007/s00277-008-0622-5. Epub 2008 Oct 14. Ann Hematol. 2009. PMID: 18853161 Review.
Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens J, Böhme A, Silling G, Martino R, Maschmeyer G, Rüping MJ, Ullmann AJ, Cornely OA. Vehreschild JJ, et al. Among authors: reichert d. Int J Antimicrob Agents. 2009 Nov;34(5):446-50. doi: 10.1016/j.ijantimicag.2009.06.025. Epub 2009 Aug 22. Int J Antimicrob Agents. 2009. PMID: 19700265 Free article.
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Proetel U, et al. Ann Hematol. 2014 Jul;93(7):1167-76. doi: 10.1007/s00277-014-2041-0. Ann Hematol. 2014. PMID: 24658964 Free PMC article. Clinical Trial.
214 results